Bayer and J&J ink $775M deal to resolve 25,000 Xarelto cases by Eric Sagonowsky Monday, March 25, 2019 Bayer and J&J agreed to pay $775 million to wrap up about 25,000 lawsuits claiming their Xarelto anticoagulant caused severe bleeding.
FDA turnabout lets generics makers keep shield against lawsuits by Eric Sagonowsky Friday, December 14, 2018 Generic drug makers scored a win at the FDA as the agency changed its mind on giving them responsibility to update their labels.
Feds to back Merck at Supreme Court in Fosamax pre-emption case by Arlene Weintraub Tuesday, December 4, 2018 The U.S. is supporting Merck in the Fosamax case, which addresses the question of whether FDA decisions shield pharma from state suits.
Bayer draws on past tactics in fighting Roundup cases by Eric Sagonowsky Wednesday, October 24, 2018 A judge struck a large portion of a Roundup verdict against Bayer, but as thousands of lawsuits pile up, the litigation is just getting started.
J&J inks Risperdal settlement days before latest trial by Eric Sagonowsky Tuesday, October 23, 2018 Right before a trial, Johnson & Johnson inked a settlement to resolve allegations its antipsychotic Risperdal caused a patient to develop breasts.
Merck rebuts petition urging SCOTUS to ignore Fosamax appeal by Arlene Weintraub Tuesday, June 12, 2018 Merck's ruling at the Supreme Court could affect liability lawsuits across Big Pharma.
Judge orders 1,200 Xarelto cases to be prepped for trials by Eric Sagonowsky Friday, March 9, 2018 A judge has ordered 1,200 Xarelto liability cases against J&J and Bayer to be prepared for trial in courts around the country.
AbbVie scores victory in third AndroGel case to reach verdict by Eric Sagonowsky Monday, January 29, 2018 AbbVie has scored a victory in its AndroGel legal saga as more than 4,000 cases await trial.
Judge overturns $28M Xarelto verdict against Bayer and J&J by Eric Sagonowsky Wednesday, January 10, 2018 A judge's new ruling means the first verdict to go against Bayer and Johnson & Johnson over Xarelto's bleeding risks won't stand.
J&J, Bayer lose first Xarelto case in $28M verdict by Eric Sagonowsky Tuesday, December 5, 2017 After three wins in cases over the risks of blockbuster blood thinner Xarelto, Bayer and Johnson & Johnson have encountered their first defeat.
